Home » Stocks » Veracyte

Veracyte, Inc. (VCYT)

Stock Price: $39.05 USD -0.40 (-1.01%)
Updated Oct 22, 2020 4:00 PM EDT - Market closed
After-hours: $39.45 +0.40 (1.02%) Oct 22, 4:15 PM

Stock Price Chart

Key Info

Market Cap 2.21B
Revenue (ttm) 112.53M
Net Income (ttm) -30.93M
Shares Out 56.58M
EPS (ttm) -0.63
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 22, 2020
Last Price $39.05
Previous Close $39.45
Change ($) -0.40
Change (%) -1.01%
Day's Open 39.76
Day's Range 38.22 - 40.60
Day's Volume 575,029
52-Week Range 13.90 - 44.64

More Stats

Market Cap 2.21B
Enterprise Value 2.07B
Earnings Date (est) Nov 2, 2020
Ex-Dividend Date n/a
Shares Outstanding 56.58M
Float 54.59M
EPS (basic) -0.64
EPS (diluted) -0.63
FCF / Share -0.32
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 3.48M
Short Ratio 7.82
Short % of Float 6.37%
Beta 0.62
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 19.64
PB Ratio 10.88
Revenue 112.53M
Operating Income -33.21M
Net Income -30.93M
Free Cash Flow -16.13M
Net Cash 135.02M
Net Cash / Share 2.39
Gross Margin 74.51%
Operating Margin -29.51%
Profit Margin -27.50%
FCF Margin -14.33%
ROA -7.55%
ROE -13.73%
ROIC -69.30%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (6)

Buy 5
Overweight 0
Hold 0
Underweight 0
Sell 1

Analyst Consensus: Buy

Price Target

$37.40*
(-4.23% downside)
Low
35.0
Current: $39.05
High
40.0
Target: 37.40
*Average 12-month price target from 5 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year201920182017201620152014201320122011
Revenue12092.0171.9565.0949.5038.1921.8811.632.65
Revenue Growth30.82%27.87%10.55%31.48%29.62%74.51%88.2%339.62%-
Gross Profit83.8558.9343.7639.6228.0121.589.284.04-0.28
Operating Income-15.13-22.23-26.54-28.80-33.47-29.01-23.17-18.93-15.27
Net Income-12.60-23.00-31.00-31.36-33.70-29.37-25.58-18.65-14.45
Shares Outstanding46.1437.0233.9328.8325.9921.644.160.650.58
Earnings Per Share-0.27-0.62-0.91-1.09-1.30-1.36-6.15-28.68-24.90
Operating Cash Flow-3.23-13.52-23.92-27.98-26.97-27.63-19.16-7.17-13.52
Capital Expenditures-2.73-1.87-1.32-4.21-6.17-2.02-1.33-1.46-0.28
Free Cash Flow-5.97-15.40-25.23-32.19-33.13-29.66-20.49-8.63-13.80
Cash & Equivalents16078.6034.4959.9439.8135.2071.3414.177.73
Total Debt13.6125.2825.2525.524.994.924.90--
Net Cash / Debt14653.329.2534.4334.8230.2866.4414.177.73
Assets27512178.6710175.2564.8479.6319.0710.45
Liabilities35.7640.8841.4441.4524.0023.4723.1914.171.92
Book Value23979.7637.2359.5851.2541.3756.44-58.47-40.77
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Veracyte, Inc.
Country United States
Employees 354
CEO Bonnie H. Anderson

Stock Information

Ticker Symbol VCYT
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: VCYT
IPO Date October 30, 2013

Description

Veracyte operates as a genomic diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to identify patients with benign thyroid nodules among those with indeterminate cytopathology results in order to rule out unnecessary thyroid surgery; Percepta Genomic Sequencing Classifier for lung cancer; Envisia Genomic Classifier that help physicians to differentiate idiopathic pulmonary fibrosis from other interstitial lung diseases without the need for surgery; and Prosigna Breast Cancer Prognostic Gene Signature Assay test for assessing risk of distant recurrence. It sells its products through product specialists, account managers, and medical science specialists. Veracyte, Inc. has a strategic collaboration with Johnson & Johnson Innovation and the Lung Cancer Initiative at Johnson & Johnson to advance the development and commercialization of novel diagnostic tests to detect lung cancer at its earliest stages; a research collaboration with Loxo Oncology for the development of therapies for patients with genetically defined cancers; and a collaboration with Johnson & Johnson Services, Inc. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.